New pill aims to wipe out lingering lymphoma cells after remission
NCT ID NCT07507318
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a drug called chidamide in people with a type of aggressive lymphoma (double-expressor DLBCL) who are in remission but still have traces of cancer DNA in their blood. The goal is to see if taking chidamide pills for up to two years can clear those hidden cancer cells and improve long-term outcomes. About 69 adults will take part across multiple hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chidamide (a type of targeted cancer pill)
What this could lead to
If successful, this could offer a way to eliminate hidden cancer cells after initial treatment, potentially delaying or preventing relapse in high-risk lymphoma patients.
What could go wrong
This is a small, early-phase study with no control group, so results may not be definitive. Chidamide can cause side effects like low blood counts and fatigue, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 20000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••